Literature DB >> 32285135

Unexpected Hair Regrowth in a Patient with Longstanding Alopecia Universalis During Treatment of Recalcitrant Dermatomyositis with the Janus Kinase Inhibitor Ruxolitinib.

Tanja Fetter1, German Cuevas Rios, Dennis Niebel, Thomas Bieber, Jörg Wenzel.   

Abstract

is missing (Short communication).

Entities:  

Keywords:  JAK/STAT pathway; dermatomyositis; interferon; janus kinase inhibitor; alopecia areata

Mesh：

Substances：

Year:  2020        PMID： 32285135      PMCID： PMC9137361          DOI： 10.2340/00015555-3481

Source DB:  PubMed          Journal:  Acta Derm Venereol        ISSN： 0001-5555            Impact factor:   3.875


  6 in total

1.  Remission of recalcitrant dermatomyositis treated with ruxolitinib.

Authors:  Thorsten Hornung; Viktor Janzen; Franz-Josef Heidgen; Dominik Wolf; Thomas Bieber; Joerg Wenzel
Journal:  N Engl J Med       Date:  2014-12-25       Impact factor: 91.245

Review 2.  Alopecia areata: a review of disease pathogenesis.

Authors:  F Rajabi; L A Drake; M M Senna; N Rezaei
Journal:  Br J Dermatol       Date:  2018-09-09       Impact factor: 9.302

3.  JAK inhibitors and alopecia areata.

Authors:  Amos Gilhar; Aviad Keren; Ralf Paus
Journal:  Lancet       Date:  2019-01-26       Impact factor: 79.321

Review 4.  Alopecia areata.

Authors:  C Herbert Pratt; Lloyd E King; Andrew G Messenger; Angela M Christiano; John P Sundberg
Journal:  Nat Rev Dis Primers       Date:  2017-03-16       Impact factor: 52.329

Review 5.  Innate immune-response mechanisms in dermatomyositis: an update on pathogenesis, diagnosis and treatment.

Authors:  Thorsten Hornung; Joerg Wenzel
Journal:  Drugs       Date:  2014-06       Impact factor: 11.431

6.  Selective Janus Kinase 1 Inhibition Is a Promising Therapeutic Approach for Lupus Erythematosus Skin Lesions.

Authors:  Tanja Fetter; Paul Smith; Tugce Guel; Christine Braegelmann; Thomas Bieber; Joerg Wenzel
Journal:  Front Immunol       Date:  2020-03-03       Impact factor: 7.561
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.